MannKind Corporation

MNKD Healthcare Biotechnology

MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024. In the quarter to June 2026, revenue grew 42.9%, EPS fell 2,827.3%, free cash flow fell 399.4% and total debt rose 201.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

3.04 0.15 −4.70%
Market cap
$1.0B
P/E
0.0×
Fwd P/E
−108×
Dividend yield
—
F-score
4/9
Altman Z
−3.63
Beneish M
0.65
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

6 4 3 2
ROE
(22.97%) (9.03%) 40.60% 71.36%
ROA
6.10% 0.99% (4.14%) (7.62%)
ROIC
0.00% 10.29% 4.05% 2.36%
Return on Tangible Assets
8.80% 2.89% (12.01%) (23.20%)
Average Days of Receivables
20.22 40.13 28.47 40.06
Free Cash Flow per Share
0.14 0.04 0.04 (0.06)
Free Cash Flow
43.39 13.69 13.15 (18.13)
Other line items

Show all line items

Columns are period end dates